(R)-4-Methyloxazolidin-2-one → (R)-3-{4-[4-(3-cyclopropyl-5-methylpyridin-2-yl)piperazine-1-carbonyl]-3-fluorophenyl}-4-methyloxazolidin-2-one
反応式
Br[C:2]1[CH:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][N:13]([C:16]3[C:21]([CH:22]4[CH2:24][CH2:23]4)=[CH:20][C:19]([CH3:25])=[CH:18][N:17]=3)[CH2:12][CH2:11]2)=[O:9])=[C:4]([F:26])[CH:3]=1.[CH3:27][C@@H:28]1[CH2:32][O:31][C:30](=[O:33])[NH:29]1>>[CH:22]1([C:21]2[C:16]([N:13]3[CH2:14][CH2:15][N:10]([C:8]([C:5]4[CH:6]=[CH:7][C:2]([N:29]5[C@H:28]([CH3:27])[CH2:32][O:31][C:30]5=[O:33])=[CH:3][C:4]=4[F:26])=[O:9])[CH2:11][CH2:12]3)=[N:17][CH:18]=[C:19]([CH3:25])[CH:20]=2)[CH2:24][CH2:23]1参加物
3
実験手順
By reaction and treatment in the same manner as in Example 1 and using (4-bromo-2-fluorophenyl)[4-(3-cyclopropyl-5-methylpyridin-2-yl)piperazin-1-yl]methanone (962 mg) described in Preparation Example 109 and (R)-4-methyloxazolidin-2-one (354 mg) described in Preparation Example 25, the title compound (990 mg) was obtained.